文献速递胸部肿瘤

卡铂联合依托泊苷加或不加帕利福酰胺治疗初治广泛期小细胞肺癌:多中心、适应性、随机III期研究(MATISSE)

Carboplatin and Etoposide With or Without Palifosfamide in Untreated Extensive-Stage Small-Cell Lung Cancer: A Multicenter, Adaptive, Randomized Phase III Study (MATISSE).
PubMed 文献 · J Clin Oncol · 2017-06-12

MATISSE研究为随机、开放标签、适应性III期试验,纳入188例初治广泛期小细胞肺癌患者。患者按1:1随机接受CE方案(卡铂曲线下面积5,第1天;依托泊苷100 mg/m2/天,第1-3天)或PaCE方案(卡铂曲线下面积4,第1天;依托泊苷100 mg/m2/天;帕利福酰胺130 mg/m2/天,第1-3天),每21天重复。主要终点总生存期在两组间相似,PaCE组中位总生存期10.03个月,CE组10.37个月(P=0.096);在CE方案基础上加入帕利福酰胺未能改善广泛期小细胞肺癌患者的生存。

要点

  • MATISSE研究纳入188例初治广泛期小细胞肺癌患者,随机接受CE或PaCE方案。
  • 两组中位总生存期分别为PaCE组10.03个月与CE组10.37个月(P=0.096)。
  • 在CE方案基础上加入帕利福酰胺未能改善广泛期小细胞肺癌患者的生存。

核心结论

  • 在卡铂联合依托泊苷方案中加入帕利福酰胺未能改善广泛期小细胞肺癌患者的生存。

研究设计与样本

  • MATISSE为随机、开放标签、适应性III期研究,共纳入188例初治广泛期小细胞肺癌患者。
  • 患者按1:1随机分配至CE组(94例)或PaCE组(94例)。

主要发现

  • 两组中位年龄均为61岁。
  • 约50%的患者在两个治疗组中均完成了6个周期的化疗。
  • 严重不良事件在PaCE组与CE组之间无显著差异。
  • 中位总生存期在PaCE组为10.03个月,在CE组为10.37个月(P=0.096)。

关键数值与推荐

  • CE方案:卡铂曲线下面积5,第1天;依托泊苷100 mg/m2/天,第1-3天;每21天重复。
  • PaCE方案:卡铂曲线下面积4,第1天;依托泊苷100 mg/m2/天,第1-3天;帕利福酰胺130 mg/m2/天,第1-3天;每21天重复。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose To evaluate the efficacy of the addition of palifosfamide to carboplatin and etoposide in extensive stage (ES) small-cell lung cancer (SCLC). Patients and Methods MATISSE was a randomized, open-label, adaptive phase III study. Previously untreated patients with ES SCLC were randomly assigned in a 1:1 fashion to receive carboplatin at area under the serum concentration-time curve 5 on day 1 plus etoposide 100 mg/m2 per day on days 1 to 3 every 21 days (CE) or carboplatin at area under the serum concentration-time curve 4 on day 1 plus etoposide 100 mg/m2 per day plus palifosfamide 130 mg/m2 per day on days 1 to 3 every 21 days (PaCE). The primary end point was overall survival. Results In all, 188 patients were enrolled; 94 patients received CE and 94 patients received PaCE. The median age on both arms was 61 years. Six cycles of chemotherapy were completed on both arms of the study by approximately 50% of the patients. Serious adverse events were documented and did not differ significantly between patients receiving PaCE and those receiving CE. Median overall survival was similar between both arms with 10.03 months on PaCE and 10.37 months on CE ( P = .096). Conclusion The addition of palifosfamide to CE failed to improve survival in ES SCLC.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Jalal SI, Lavin P, Lo G, et al. Carboplatin and Etoposide With or Without Palifosfamide in Untreated Extensive-Stage Small-Cell Lung Cancer: A Multicenter, Adaptive, Randomized Phase III Study (MATISSE). J Clin Oncol. 2017. PMID: 28605291. doi:10.1200/JCO.2016.71.7454

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。